Coya Therapeutics (NASDAQ:COYA) Given Buy Rating at Chardan Capital

Coya Therapeutics (NASDAQ:COYA - Get Free Report)'s stock had its "buy" rating reiterated by Chardan Capital in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $14.00 price objective on the stock. Chardan Capital's price objective suggests a potential upside of 123.46% from the stock's previous close.

A number of other brokerages have also issued reports on COYA. D. Boral Capital reiterated a "buy" rating and issued a $18.00 price target on shares of Coya Therapeutics in a research note on Tuesday, April 22nd. HC Wainwright reiterated a "buy" rating and set a $18.00 target price on shares of Coya Therapeutics in a research report on Monday, June 9th. Finally, Wall Street Zen cut Coya Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd.

Coya Therapeutics Stock Up 8.4%

COYA traded up $0.49 during trading on Tuesday, hitting $6.27. The company's stock had a trading volume of 72,677 shares, compared to its average volume of 72,346. The business's 50 day simple moving average is $5.83 and its 200-day simple moving average is $5.99. The firm has a market cap of $104.78 million, a PE ratio of -5.86 and a beta of 0.26. Coya Therapeutics has a one year low of $4.65 and a one year high of $10.24.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.44) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.44). The company had revenue of $257.88 million for the quarter, compared to the consensus estimate of $2.63 million. Equities research analysts expect that Coya Therapeutics will post -1.15 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Tower Research Capital LLC TRC increased its holdings in shares of Coya Therapeutics by 1,005.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company's stock worth $30,000 after purchasing an additional 4,777 shares during the last quarter. XTX Topco Ltd purchased a new position in Coya Therapeutics during the 4th quarter valued at approximately $59,000. Charles Schwab Investment Management Inc. bought a new stake in Coya Therapeutics in the 1st quarter worth approximately $65,000. Jane Street Group LLC bought a new stake in Coya Therapeutics in the 4th quarter worth approximately $74,000. Finally, Northern Trust Corp raised its holdings in shares of Coya Therapeutics by 12.2% during the 4th quarter. Northern Trust Corp now owns 28,549 shares of the company's stock worth $164,000 after acquiring an additional 3,099 shares in the last quarter. Institutional investors own 39.75% of the company's stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.